Texas Saxenda Lawsuit Attorneys

A Saxenda gastroparesis lawsuit is brought by individuals who developed gastroparesis( stomach paralysis) after using the GLP-1 weight loss medication. Gastroparesis causes nausea, vomiting, bloating, and inability to digest food, often necessitating hospitalization, feeding tubes, or surgery. Despite growing evidence and allegations of stomach muscle and digestion issues associated with stomach paralysis, the manufacturer never added gastroparesis to Saxenda’s label.

Saxenda lawsuits claim the company failed to disclose this life-altering health complication, leaving users unable to make informed decisions regarding their medical treatment

Saxenda Gastroparesis Stomach Paralysis and Delayed Gastric Emptying

Saxenda has been linked to gastrointestinal disorders such as delayed gastric emptying, where the stomach takes too long to move food into the small intestine. Those suffering from this condition allege significant health issues, including chronic bloating, nausea, and difficulty maintaining proper nutrition. Legal claims continue to grow as more individuals come forward with similar diagnoses following Saxenda use.

Legal Claims for Severe Vomiting, Early Satiety, and Other Gastrointestinal Complications

Ongoing Saxenda cases highlight many gastrointestinal problems, including vomiting and early satiety, that disrupt users’ ability to eat and maintain their health. These symptoms have triggered growing safety concerns. Our Texas Saxenda attorneys are working to hold the manufacturer accountable for failing to provide proper warnings to healthcare providers.

Some people taking Saxenda have developed acute pancreatitis, a painful and potentially dangerous inflammation of the pancreas. This condition can require hospitalization and lead to long-term health problems if not treated promptly.

Saxenda gallbladder lawsuits involve those who developed gallbladder disease, gallstones, cholecystitis, or bile duct obstruction after using the drug. Rapid weight loss triggered by Saxenda use can increase bile concentration and reduce gallbladder function. Some users also experienced bile duct injury during emergency surgical procedures. While the manufacturer did warn about gallbladder problems, they downplayed the frequency and severity of gallbladder disorders.

Can Saxenda Cause Gallstones?

Yes, taking Saxenda can cause gallstones by triggering rapid weight loss, which increases bile concentration and reduces gallbladder emptying.

Bile duct-related health complications can occur when gallstones block the ducts, leading to pain, infection, or liver damage. Some Saxenda users required emergency surgical procedures, during which bile ducts were accidentally injured or inflamed. This can cause long-term digestive issues and may require additional procedures to repair.

Some patients taking Saxenda have alleged vision loss tied to non-arteritic anterior ischemic optic neuropathy (NAION). Plaintiffs argue that users were unaware of this potential risk.

The weight loss drug has been linked to kidney disease and kidney failure, especially in patients who experience severe dehydration due to vomiting or diarrhea. Kidney issues can require dialysis or result in permanent damage.

Patients diagnosed with bowel obstruction, ileus, or intestinal blockage after taking the weight loss drug are suing Novo Nordisk because they weren’t made aware of these stomach problems.

The drug’s label did not list these specific stomach problems, like bowel obstruction and other forms of intestinal blockage, despite post-marketing researchers tying intestinal obstruction to GLP-1 drugs.

Some patients taking Saxenda have reported serious blood clot complications, including deep vein thrombosis (DVT) and pulmonary embolism. These conditions can lead to hospitalization or death if not treated promptly.

Our Saxenda attorney team is working to ensure the negligent drug company is held accountable for failing to disclose the full extent of the conditions and for not providing adequate warnings to patients and healthcare providers.

In extreme cases, Saxenda has been linked to cardiovascular events, including a heart attack. While these reports remain under investigation, legal claims suggest that patients with underlying conditions may face increased risks. Plaintiffs allege that Novo Nordisk did not fully inform users of the drug’s potential impact on heart health.

While not approved to treat type 2 diabetes, researchers have tied this GLP-1 drug to low blood sugar in some users. Reported symptoms of hypoglycemia include dizziness, confusion, sweating, and fainting. This raises concerns about the drug’s impact on glucose regulation, especially in patients without a history of diabetes.

Metabolic crisis after using Saxenda can occur when rapid weight loss, dehydration, malnutrition, or prolonged vomiting severely disrupts the body’s electrolyte balance and energy metabolism.

The Food and Drug Administration label notes serious gastrointestinal complications, including pancreatitis and gallbladder disease, as well as risks tied to rapid weight loss, including dehydration and kidney damage. Patients allege that the manufacturer failed to warn patients adequately about the life-threatening outcomes of metabolic crisis.

Some Saxenda users have reported serious liver-related side effects, including liver disease, hepatitis, and liver damage. These conditions may result from the body’s reaction to the drug’s active ingredient and are now being reviewed in connection with growing Saxenda lawsuit filings.

Patients taking Saxenda for weight loss who experience symptoms such as fatigue, jaundice, or dark urine are encouraged to seek medical attention, as these may indicate liver complications requiring prompt evaluation.